Autolus (AUTL) Schedule 13G/A: Wellington Reports 0.0% Stake
Wellington Management filed an amended Schedule 13G reporting its position in Autolus Therapeutics plc (AUTL) common stock.
Rhea-AI Filing Summary
Wellington Management filed an amended Schedule 13G reporting its position in Autolus Therapeutics plc (AUTL) common stock. The filing lists three related Wellington entities organized in MASSACHUSETTS and DELAWARE that collectively report 0.0% beneficial ownership of the class and 0 shares of sole voting or dispositive power. The securities are owned of record by clients of Wellington investment advisers and are held in the ordinary course of business, with no client reported as having more than 5% of the class. The cover lists the issuer address in London and the event date 09/30/2025; the filing is signed on 10/07/2025 by a Wellington regulatory analyst.
Positive
- Clear disclosure of entity structure and reporting chain among Wellington affiliates
- Certifies ordinary-course holdings and explicitly states no client holds more than 5% of the class
- Timely amendment with event date 09/30/2025 and signature dated 10/07/2025
Negative
- No beneficial ownership reported (0.0%), indicating no economic or voting exposure from these filers
Insights
TL;DR: Wellington reports no beneficial stake in AUTL as of 09/30/2025.
The filing identifies three Wellington-related entities and multiple Wellington investment advisers as record owners for client accounts, but shows an aggregate beneficial ownership of 0.0% and zero shares of sole or shared voting and dispositive power. This indicates Wellington does not hold a reportable economic or voting position in the common stock class.
The position is described as held in the ordinary course of business with no client exceeding 5% of the class. Investors looking for changes in ownership should note the 09/30/2025 event date and the 10/07/2025 signature; subsequent filings would disclose any new positions.
TL;DR: This Schedule 13G/A confirms non-activist, non-controlling record holdings by Wellington-affiliated advisers.
The statement certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing control. The filing lists parent/subsidiary relationships among Wellington entities, clarifying reporting chain and the advisers exercising record ownership for clients.
Key governance watchers should note there is no group formation or >5% ownership disclosed, so there are no reported voting blocs or control-related disclosures tied to these Wellington entities at the stated date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Schedule 13G/A filed by Wellington mean for AUTL (AUTL) ownership?
Who filed the Schedule 13G/A for Autolus Therapeutics (AUTL)?
What date does the filing cover and when was it signed?
Does Wellington claim any intent to influence control of Autolus Therapeutics (AUTL)?
Are any Wellington clients reported as owning more than 5% of AUTL?
AI-generated analysis. How Rhea-AI works. Not financial advice.